thebench.bio #1 Ecosystem for the Bio-Tech Industry

Clinical Daily Summary

Clinical Daily Summary: What Happened on November 16, 2026

Amylyx reports 55% fewer hypoglycemic events with avexitide in Phase 3

CG Oncology reported lower bladder-cancer recurrence risk, while Helus’s depression result came with safety questions.

  • Updated
  • Read from 9 articles, 5 publications
  • P B A

Today in brief

Amylyx said avexitide cut the combined rate of confirmed moderate and severe hypoglycemic events by 55% versus placebo in a 78-person Phase 3 trial.1 In a separate 367-person Phase 3 study, CG Oncology reported a 68% lower bladder-tumor recurrence risk with cretostimogene than with no post-surgery treatment.23

Helus said its psychedelic candidate reduced depression scores more than placebo at six and 12 weeks, but several serious adverse events raised safety concerns.4

Avexitide reduced hypoglycemic events in a Phase 3 trial

Amylyx’s investigational drug avexitide cut the combined weekly rate of confirmed Level 2 and adjudicated Level 3 hypoglycemic events by 55% versus placebo during the 16-week blinded phase.1 The least-squares mean rate was 0.55 events per week with avexitide and 1.24 with placebo, a statistically significant difference.1

The randomized study enrolled 78 adults whose hypoglycemia developed after Roux-en-Y gastric bypass surgery.1 It also met secondary event-rate endpoints, including reductions of 63% in Level 2 events and 47% in Level 3 events.1

Reported side effects were mainly mild-to-moderate gastrointestinal or injection-site problems. There were no treatment-related serious adverse events or deaths.1 The FDA had granted avexitide a designation for post-bariatric hypoglycemia.1

Cretostimogene cut bladder-cancer recurrence risk by 68%

CG Oncology reported that cretostimogene was associated with a 68% lower recurrence risk than the control arm in the Phase 3 PIVOT-006 study.23 The trial enrolled 367 people with intermediate-risk or high-grade Ta non-muscle-invasive bladder cancer after complete tumor removal. Median follow-up was 17 months.3

The control group received no intervention after surgery.3 Cretostimogene is an engineered common cold virus delivered into the bladder through a catheter.2

The study reported no treatment-related adverse events of Grade 3 or higher and no treatment-related discontinuations.3 CG Oncology said it expects to submit an expanded biologics license application for these patient groups in the second quarter of 2027.3

Helus reports depression benefit alongside serious adverse events

Helus Pharma said its psychedelic candidate improved depression symptoms in a Phase 3 trial when added to participants’ usual antidepressants.4 At six weeks, scores on the Montgomery–Åsberg Depression Rating Scale fell by 19.5 points in the treatment group and 11.9 points with placebo.4

At 12 weeks, scores fell by 16.9 points with the drug and 9.9 points with placebo. The between-group differences were statistically significant at both time points.4 Most of the treatment-group improvement was sustained through week 12.4

The study had several serious adverse events, prompting questions about safety.4

Also worth knowing

  • A post hoc analysis of the 3,417-person REDEFINE 1 trial found that 67.8% of CagriSema recipients had lost at least 5% of their starting weight by week eight. Early responders had greater average weight loss by week 68 than delayed responders, 25.4% versus 17.8%.5

  • Aclaris Therapeutics’ bosakitug missed the primary and secondary endpoints in its Phase 2 atopic dermatitis trial. The company reported target engagement and said the drug was generally well tolerated.6

  • P

    PlaqueTec’s BIOPATTERN trial recruited its 100th participant and is operating at eight NHS cardiac centers, with a target of 300 participants by 2027.7

  • B

    Ossium Health’s initial 12-patient study of deceased-donor bone marrow transplants is fully enrolled. The company says its product can reach transplant centers in as little as 31 hours, compared with a usual 12-to-15-week timeline.8

  • A

    A survey of 354 prescreening respondents found that users of AI voice screening were more likely than web-form users to schedule and attend appointments. Because participants self-selected their screening method, the association does not establish causation.9

Also published